Alzheimer’s Disease/Dementia News

CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.

WEST PALM BEACH, Fla. — Variability and length of pauses in speech may indicate cognitive impairment for German-speaking individuals with multiple sclerosis, according to a poster from ACTRIMS 2024.

The FDA will convene an advisory committee meeting to discuss the safety and efficacy of donanemab in early symptomatic Alzheimer's disease, according to the manufacturer.

The FDA has granted breakthrough device designation to a phospho-tau 217 blood-based biomarker to assist in the diagnosis of Alzheimer’s disease, according to the manufacturer.

Quanterix Corp. has announced collaborations with several health systems with the goal of improving and simplifying Alzheimer’s disease diagnosis by expanding access to blood biomarker assays.

Researchers reported that a population-based study shows statin use among older adults with heart failure was associated with a 20% lower risk for all-cause dementia, including a 28% reduction in risk for developing Alzheimer’s disease.

Otsuka has announced that a phase 3 clinical trial of AVP-786, a combination therapy to treat agitation associated with dementia due to Alzheimer’s disease, failed to achieve its primary endpoints.

Older adults with a coronary artery calcium score of 0 had more favorable aging indices, including normal cognitive function, vascular function and better hearing, compared with those with CAC scores of 1,000 or greater, data show.

A program geared toward diabetes management in the primary care setting helped to reduce patients’ risk for dementia — including Alzheimer’s disease — according to researchers.

The FDA has granted breakthrough therapy designation to latozinemab, an investigational therapeutic designed to block sortilin and elevate progranulin to treat frontotemporal dementia with a progranulin gene mutation.